Intrarectal Vaccination with Recombinant Vaccinia Virus Expressing Carcinoembronic Antigen Induces Mucosal and Systemic Immunity and Prevents Progression of Colorectal Cancer
- 1 December 2008
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 181 (11), 8112-8119
- https://doi.org/10.4049/jimmunol.181.11.8112
Abstract
The gastrointestinal mucosa contains an intact immune system that protects the host from pathogens and communicates with the systemic immune system. Absorptive epithelial cells in the mucosa give rise to malignant tumors although the interaction between tumor cells and the mucosal immune system is not well defined. The pathophysiology of colorectal cancer has been elucidated through studies of hereditary syndromes, such as familial adenomatous polyposis, a cancer predisposition syndrome caused by germline mutations in the adenomatous polyposis coli tumor suppressor gene. Patients with FAP develop adenomas and inevitably progress to invasive carcinomas by the age of 40. To better delineate the role of mucosal immunity in colorectal cancer, we evaluated the efficacy of intrarectal recombinant vaccinia virus expressing the human carcinoembryonic Ag (CEA) in a murine FAP model in which mice are predisposed to colorectal cancer and also express human CEA in the gut. Mucosal vaccination reduced the incidence of spontaneous adenomas and completely prevented progression to invasive carcinoma. The therapeutic effects were associated with induction of mucosal CEA-specific IgA Ab titers and CD8+ CTLs. Mucosal vaccination was also associated with an increase in systemic CEA-specific IgG Ab titers, CD4+ and CD8+ T cell responses and resulted in growth inhibition of s.c. implanted CEA-expressing tumors suggesting communication between mucosal and systemic immune compartments. Thus, intrarectal vaccination induces mucosal and systemic antitumor immunity and prevents progression of spontaneous colorectal cancer. These results have implications for the prevention of colorectal cancer in high-risk individuals.Keywords
This publication has 45 references indexed in Scilit:
- Poxvirus-based vaccine therapy for patients with advanced pancreatic cancerJournal of Translational Medicine, 2007
- A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β– and retinoic acid–dependent mechanismThe Journal of Experimental Medicine, 2007
- Mechanism and Therapeutic Reversal of Immune Suppression in CancerCancer Research, 2007
- Intrarectal Immunization with Rotavirus 2/6 Virus-Like Particles Induces an Antirotavirus Immune Response Localized in the Intestinal Mucosa and Protects against Rotavirus Infection in MiceJournal of Virology, 2006
- Immune suppression by tumor-specific CD4+ regulatory T-cells in cancerSeminars in Cancer Biology, 2006
- Induction of Mucosal and Systemic Immune Responses against Human Carcinoembryonic Antigen by an Oral VaccineCancer Research, 2005
- Selective imprinting of gut-homing T cells by Peyer's patch dendritic cellsNature, 2003
- Serum HCGβ, CA 72‐4 and CEA are independent prognostic factors in colorectal cancerInternational Journal of Cancer, 2002
- Intestinal dendritic cells increase T cell expression of α4β7 integrinEuropean Journal of Immunology, 2002
- A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA)International Journal of Cancer, 1991